On Jul. 10, 2020, Gilead Sciences announced that a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19. In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62 percent reduction in the risk of mortality compared with standard of care ﾖ an important finding that requires confirmation in prospective clinical trials.